NeuroPsy InfoHub adună studii și articole verificate editorial despre sănătate mintală și afecțiuni neurologice — pentru pacienți, familii și specialiști.
This study uses MRI to investigate structural brain changes associated with major depressive disorder, examining cortical thinning patterns across brain regions. The research contributes to understanding the neurobiological mechanisms underlying depression, moving beyond symptom description toward identifying neural signatures of the condition.
This protocol describes a double-blinded, sham-controlled randomised trial evaluating transcranial pulsed electromagnetic field (T-PEMF) treatment delivered via a MoodHeadBand for patients with moderate to severe depression who have not responded to conventional therapies. The 8-week study measures depressive symptoms, cognitive function, and sleep quality using validated clinical instruments in 96 participants.
This scoping review synthesizes evidence on assessment methods and interventions for sleep disturbances in depressed adolescents, analyzing 26 peer-reviewed studies published 2000-2024. The review examines evidence-based approaches including cognitive-behavioral therapy for insomnia (CBT-I), mindfulness interventions, melatonin use, and psychoeducation, with CBT-I demonstrating consistent efficacy in addressing the bidirectional relationship between mood and sleep disorders.
This qualitative study explores patient experiences and perspectives on anhedonia (loss of pleasure) as a symptom of major depressive disorder, examining barriers to discussion and management strategies. The research identifies patient-identified challenges and opportunities for improving clinical communication and treatment approaches for this core depressive symptom.
This systematic review evaluates how different antidepressant classes affect insulin resistance, a metabolic complication common in depression. Tricyclic antidepressants (nortriptyline, amitriptyline, imipramine) worsen insulin sensitivity, while SSRIs and SNRIs appear metabolically neutral; bupropion and agomelatine show potential metabolic benefits in diabetic patients.
